{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:14:51Z","timestamp":1793394891411,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015696","name":"Siemens Healthineers USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015696","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.aohep.2025.101789","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T11:31:16Z","timestamp":1739014276000},"page":"101789","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Economic evaluation of non-invasive test pathways for high-risk metabolic dysfunction-associated steatotic liver disease (MASLD) in the United Kingdom (UK)"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-577X","authenticated-orcid":false,"given":"Zobair M.","family":"Younossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Pollock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Stepanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema","family":"Nader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.aohep.2025.101789_bib0001","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL\u2013Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality","volume":"399","author":"Karlsen","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2025.101789_bib0002","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.aohep.2025.101789_bib0003","article-title":"Baveno Cooperation: an EASL consortium. Risk of further decompensation\/mortality in patients with cirrhosis and ascites as the first single decompensation event","volume":"4","author":"Balcar","year":"2022","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.aohep.2025.101789_bib0004","doi-asserted-by":"crossref","first-page":"101133","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella","year":"2024","journal-title":"Ann Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101789_bib0005","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.aohep.2025.101789_bib0006","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jceh.2022.12.005","article-title":"The growing economic and clinical burden of nonalcoholic steatohepatitis (NASH) in the United States","volume":"13","author":"Younossi","year":"2023","journal-title":"J Clin Exp Hepatol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101789_bib0007","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jhep.2021.05.022","article-title":"Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: data from Global Burden of Disease 2009\u20132019","volume":"75","author":"Golabi","year":"2021","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.aohep.2025.101789_bib0008","doi-asserted-by":"crossref","first-page":"e0251","DOI":"10.1097\/HC9.0000000000000251","article-title":"The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019","volume":"7","author":"Paik","year":"2023","journal-title":"Hepatol Commun"},{"issue":"5","key":"10.1016\/j.aohep.2025.101789_bib0009","doi-asserted-by":"crossref","first-page":"310","DOI":"10.4103\/sjg.sjg_62_24","article-title":"The burden of metabolic dysfunction-associated steatotic liver disease and viral hepatitis in Saudi Arabia","volume":"30","author":"Alqahtani","year":"2024","journal-title":"Saudi J Gastroenterol"},{"issue":"11","key":"10.1016\/j.aohep.2025.101789_bib0010","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/hep4.1765","article-title":"Poor awareness of liver disease among adults with NAFLD in the United States","volume":"5","author":"Alqahtani","year":"2021","journal-title":"Hepatol Commun"},{"issue":"6","key":"10.1016\/j.aohep.2025.101789_bib0011","doi-asserted-by":"crossref","first-page":"e1456","DOI":"10.1016\/j.cgh.2021.06.048","article-title":"Global Nonalcoholic Steatohepatitis Council. A global survey of physicians' knowledge about nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2025.101789_bib0012","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.aohep.2025.101789_bib0013","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"Fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD)","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"3","key":"10.1016\/j.aohep.2025.101789_bib0014","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"10.1016\/j.aohep.2025.101789_bib0015","first-page":"S52","article-title":"Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes\u20132024","volume":"47","year":"2024","journal-title":"Diabet Care"},{"key":"10.1016\/j.aohep.2025.101789_bib0016","doi-asserted-by":"crossref","unstructured":"Anstee QM, Berentzen TL, Nitze LM, Jara M, Jensen AB, Kj\u00e6r MS, et al. Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and\/or type 2 diabetes: a longitudinal cohort study. Lancet Reg Health Eur. 2023;36:100780. doi: 10.1016\/j.lanepe.2023.100780.","DOI":"10.1016\/j.lanepe.2023.100780"},{"key":"10.1016\/j.aohep.2025.101789_bib0017","unstructured":"American Association for the Study of Liver Diseases (AASLD). Why are non-invasive risk scores, such as FIB-4, used? Accessed December 18, 2024. Available from: https:\/\/www.aasld.org\/liver-fellow-network\/core-series\/why-series\/why-are-non-invasive-risk-scores-such-fib-4-used"},{"issue":"4","key":"10.1016\/j.aohep.2025.101789_bib0018","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/liv.15852","article-title":"Prevalence of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa","volume":"44","author":"Younossi","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2025.101789_bib0019","article-title":"Pharmaco-economic assessment of screening strategies for high-risk MASLD in primary care","author":"Younossi","year":"2024","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.aohep.2025.101789_bib0020","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12876-019-1039-4","article-title":"Cost-comparison analysis of FIB-4, ELF and fibroscan in community pathways for non-alcoholic fatty liver disease","volume":"19","author":"Srivastava","year":"2019","journal-title":"BMC Gastroenterol"},{"issue":"4","key":"10.1016\/j.aohep.2025.101789_bib0021","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.aohep.2025.101789_bib0022","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.cgh.2022.07.033","article-title":"Disease State transition probabilities across the spectrum of NAFLD: a systematic review and meta-analysis of paired biopsy or imaging studies","volume":"21","author":"Le","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.aohep.2025.101789_bib0023","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.30426","article-title":"Analysis of a simulation model to estimate long-term outcomes in patients with nonalcoholic fatty liver disease","volume":"5","author":"Chhatwal","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.aohep.2025.101789_bib0024","unstructured":"Global NASH Registry. MASH prevalence and clinical data. [Unpublished raw data]. Retrieved from: https:\/\/www.globalnashcouncil.org\/gnc-registries\/. Accessed February 12, 2024."},{"issue":"3","key":"10.1016\/j.aohep.2025.101789_bib0025","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/apt.18451","article-title":"Meta-analysis: global prevalence and mortality of cirrhosis in metabolic dysfunction-associated steatotic liver disease","volume":"61","author":"Owrangi","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.aohep.2025.101789_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(24)01451-X","article-title":"Projected economic burden of metabolic dysfunction-associated steatohepatitis in the US, Germany, Spain, Saudi Arabia, Brazil, and Japan","author":"Younossi","year":"2024","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.aohep.2025.101789_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2009.06.007","article-title":"Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease","volume":"7","author":"Hossain","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10258","key":"10.1016\/j.aohep.2025.101789_bib0028","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2025.101789_bib0029","unstructured":"Global Observatory on Donation and Transplantation (GODT). Global liver donation and transplantation data. Available at: https:\/\/www.transplant-observatory.org. Accessed February 12, 2024."},{"key":"10.1016\/j.aohep.2025.101789_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.840299","article-title":"Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis","volume":"13","author":"Lian","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10440","key":"10.1016\/j.aohep.2025.101789_bib0031","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","year":"2024","journal-title":"Lancet."},{"issue":"1","key":"10.1016\/j.aohep.2025.101789_bib0032","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12916-018-1103-x","article-title":"Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease","volume":"16","author":"Alexander","year":"2018","journal-title":"BMC Med"},{"issue":"2","key":"10.1016\/j.aohep.2025.101789_bib0033","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jhep.2019.03.033","article-title":"Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease","volume":"71","author":"Srivastava","year":"2019","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.aohep.2025.101789_bib0034","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1111\/liv.14628","article-title":"Cost-effectiveness of strategies to improve HCV screening, linkage-to-care and treatment in remand prison settings in England","volume":"40","author":"Mohamed","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.aohep.2025.101789_bib0035","series-title":"Cirrhosis in over 16s: assessment and management | guidance","year":"2016"},{"key":"10.1016\/j.aohep.2025.101789_bib0036","series-title":"Non-Alcoholic fatty liver disease (NAFLD): assessment and management | guidance","year":"2016"},{"key":"10.1016\/j.aohep.2025.101789_bib0037","series-title":"FibroScan for assessing liver fibrosis and cirrhosis in primary care: medtech innovation briefing [MIB2016]","year":"2020"},{"key":"10.1016\/j.aohep.2025.101789_bib0038","series-title":"MRI-Based technologies for assessing non-alcoholic fatty liver disease | guidance","year":"2023"},{"issue":"7","key":"10.1016\/j.aohep.2025.101789_bib0039","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/hep4.1710","article-title":"Improvements of fibrosis and disease activity are associated with improvement of patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis","volume":"5","author":"Younossi","year":"2021","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.aohep.2025.101789_bib0040","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2016-000106","article-title":"Assessment of health utilities and quality of life in patients with non-alcoholic fatty liver disease","volume":"3","author":"Sayiner","year":"2016","journal-title":"BMJ Open Gastroenterol"},{"issue":"1","key":"10.1016\/j.aohep.2025.101789_bib0041","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12916-018-1103-x","article-title":"Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease","volume":"16","author":"Alexander","year":"2018","journal-title":"BMC Med"},{"issue":"6","key":"10.1016\/j.aohep.2025.101789_bib0042","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/MEG.0b013e32835d72cf","article-title":"Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?","volume":"25","author":"McPherson","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2025.101789_bib0043","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1007\/s00330-015-3731-2","article-title":"Cost-utility analysis of nonalcoholic steatohepatitis screening","volume":"25","author":"Zhang","year":"2015","journal-title":"Eur Radiol"},{"key":"10.1016\/j.aohep.2025.101789_bib0044","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s10620-016-4044-2","article-title":"Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: a cost-effectiveness analysis","volume":"61","author":"Corey","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.aohep.2025.101789_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147237","article-title":"Cost-effectiveness analysis: risk stratification of nonalcoholic fatty liver disease (NAFLD) by the primary care physician using the NAFLD fibrosis score","volume":"11","author":"Tapper","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.aohep.2025.101789_bib0046","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL\u2013Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality","volume":"399","author":"Karlsen","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.aohep.2025.101789_bib0047","doi-asserted-by":"crossref","DOI":"10.1111\/liv.15674","article-title":"The NAFLD burden on mortality and morbidities in general population: a community-based longitudinal study (NASH-CO study)","author":"Nabi","year":"2023","journal-title":"Liver Int"},{"issue":"10286","key":"10.1016\/j.aohep.2025.101789_bib0048","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1016\/S0140-6736(20)32396-5","article-title":"New dimensions for hospital services and early detection of disease: a review from the Lancet Commission into liver disease in the UK","volume":"397","author":"Williams","year":"2021","journal-title":"Lancet."},{"key":"10.1016\/j.aohep.2025.101789_bib0049","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1186\/1471-2458-11-603","article-title":"Emotional impact of screening: a systematic review and meta-analysis","volume":"11","author":"Collins","year":"2011","journal-title":"BMC Public Health"},{"issue":"12","key":"10.1016\/j.aohep.2025.101789_bib0050","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S2468-1253(23)00334-5","article-title":"Liver disease admissions in the UK are increasing, urgently needing local and national solutions","volume":"8","author":"Bhala","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.aohep.2025.101789_bib0051","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis","volume":"73","author":"Vali","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.aohep.2025.101789_bib0052","unstructured":"NICE- diagnostics consultation document FibroScan for assessing liver fibrosis and cirrhosis in primary or community care. Obtained from the world wide web at: https:\/\/www.nice.org.uk\/guidance\/dg48\/documents\/consultation-document. Last accessed on 1\/12\/2024."}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268125000134?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268125000134?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T09:36:31Z","timestamp":1764668191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268125000134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1665268125000134"],"URL":"https:\/\/doi.org\/10.1016\/j.aohep.2025.101789","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic evaluation of non-invasive test pathways for high-risk metabolic dysfunction-associated steatotic liver disease (MASLD) in the United Kingdom (UK)","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.aohep.2025.101789","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"101789"}}